Aurinia Pharmaceuticals Inc (AUPH) Q1 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Greetings and welcome to the Aurinia Pharmaceuticals Inc. Q1 2025 earnings call. At this time, all participants are in listen-only mode. If anyone should require operator assistance, please press star zero on your telephone keypad. A question and answer session will follow the formal presentation, and you may press star one at any time to be placed into question queue. As a reminder, this conference is being recorded. It's now my pleasure to turn the call over to Andrea Christopher, Corporate Communications and Investor Relations. Please go ahead, Andrea. Thank you, Operator, and thank you to everyone for joining today's call and webcast. Joining me on the call this morning are Peter Greenleaf, Arania's President and Chief Executive Officer, Joe Miller, Arania's Chief Financial Officer, and Dr. Greg Keenan, Arania's Chief Medical Officer. Today, we will review and discuss Arania's first quarter 2025 financial results and provide an update on recent corporate progress as communicated in the company's press release and quarterly report on Form 10Q issued this morning. For more information, please refer to Arrhenius' filings with the U.S. Securities and Exchange Commission and Canadian Securities Authorities, which are also available on Arrhenius' website at arrheniapharma.com. During today's call, Arrhenius may make forward-looking statements based on current expectations. These forward-looking statements are subject to a number of significant risks and uncertainties, and actual results may differ materially. For discussion of factors that could affect Arrhenius' future financial results in business, please refer to the disclosures in Arrhenius' press release, quarterly report on Form 10-Q, and all other filings with the U.S. Securities and Exchange Commission and Cana...